Display options
Share it on

Eur J Intern Med. 2022 Jan 06; doi: 10.1016/j.ejim.2021.12.026. Epub 2022 Jan 06.

One-year mepolizumab for Allergic bronchopulmonary aspergillosis: Focus on steroid sparing effect and markers of response.

European journal of internal medicine

Marco Caminati, Veronica Batani, Lucia Guidolin, Giuliana Festi, Gianenrico Senna

Affiliations

  1. Department of Medicine, University of Verona, Verona, Italy. Electronic address: [email protected].
  2. Department of Medicine, University of Verona, Verona, Italy.
  3. Pneumology Unit, Verona University Hospital, Verona, Italy.
  4. Department of Medicine, University of Verona, Verona, Italy; Allergy Unit and Asthma Center, University of Verona and Verona University Hospital, Verona, Italy. Electronic address: [email protected].

PMID: 34998664 DOI: 10.1016/j.ejim.2021.12.026

[No abstract available.]

Keywords: Allergic bronchopulmonary aspergillosis; Eosinophils; Mepolizumab; Severe asthma; Steroid-sparing

Publication Types